Cellular senescence of fibro-adipogenic progenitors by STAT5A/GFPT2/O-GlcNAcylation impairs muscle recovery after glucocorticoid-induced injury.
Key claim: Glucocorticoids induce fibro-adipogenic progenitor (FAP) senescence via a STAT5A/GFPT2/O-GlcNAcylation axis, and senescent FAPs impair skeletal muscle recovery by suppressing myotube formation and muscle stem cell proliferation.
Abstract
The clinical use of glucocorticoids often leads to skeletal muscle injury, characterized by muscle atrophy and dysfunction. Fibro-adipogenic progenitors (FAPs) play an important role in maintaining muscle homeostasis, but their roles in the recovery of skeletal muscle after glucocorticoid-induced injury remain largely elusive. Here, we reveal that glucocorticoid induces cellular senescence of FAPs, leading to their accumulation in skeletal muscle. Mechanistically, glucocorticoid enhances the expression of GFPT2 through STAT5A, which further elevates O-GlcNAcylation in FAPs and promotes their senescence. Targeting the STAT5A-GFPT2-mediated O-GlcNAcylation can reduce the burden of senescent FAPs in glucocorticoid-treated muscle and facilitate muscle recovery after injury. Our results demonstrate that exosomes derived from senescent FAPs suppress myotube formation, greatly inhibiting the regrowth of glucocorticoid-treated skeletal muscle. Moreover, senescent FAPs reduce the muscle stem cells (MuSCs) pool by suppressing their proliferation, thereby impairing the regenerative capacity of skeletal muscle during the recovery process after glucocorticoid treatment.
Why this matters
Glucocorticoids are among the most widely prescribed drugs and are already implicated in steroid myopathy; this finding places a specific senescence program in fibro-adipogenic progenitors — not in the muscle stem cells themselves — as the cellular substrate that blunts recovery after steroid exposure. It expands the tissue-specific senescence roster into a clinically common iatrogenic injury context and nominates a druggable STAT5A/GFPT2/O-GlcNAcylation axis upstream of the FAP SASP, though the evidence remains preclinical.